| Attributes | Values |
|---|
| rdf:type
| |
| Description
| - Background: Combined diphtheria-tetanus-whole-cell pertussis (DTPw) vaccines remain the cornerstone of many childhood vaccination programs. Larger DTPw-based combination vaccines facilitate high coverage and protection against other childhood pathogens, such as hepatitis B (HBV) and Haemophilus influenzae type b (Hib). Such vaccines have been available since the mid-1990s (Tritanrix-HBV and Tritanrix-HBV/Hib; GlaxoSmithKline [GSK] Biologicals), demonstrating excellent immunogenicity in various schedules. In order to address growing demand for DTPw-based vaccines, GSK Biologicals have developed the Zilbrix range using a new DTPw antigen source and containing reduced quantities of polyribosylribitol phosphate [PRP]. Objective: This article presents clinical trial results for both DTPw-based vaccines. Methods: GSK Biologicals provided a comprehensive data package, which was supplemented with a Medline literature search. Conclusion: New antigen sources and reduced PRP will ensure the continued supply of D
- Background: Combined diphtheria-tetanus-whole-cell pertussis (DTPw) vaccines remain the cornerstone of many childhood vaccination programs. Larger DTPw-based combination vaccines facilitate high coverage and protection against other childhood pathogens, such as hepatitis B (HBV) and Haemophilus influenzae type b (Hib). Such vaccines have been available since the mid-1990s (Tritanrix-HBV and Tritanrix-HBV/Hib; GlaxoSmithKline [GSK] Biologicals), demonstrating excellent immunogenicity in various schedules. In order to address growing demand for DTPw-based vaccines, GSK Biologicals have developed the Zilbrix range using a new DTPw antigen source and containing reduced quantities of polyribosylribitol phosphate [PRP]. Objective: This article presents clinical trial results for both DTPw-based vaccines. Methods: GSK Biologicals provided a comprehensive data package, which was supplemented with a Medline literature search. Conclusion: New antigen sources and reduced PRP will ensure the continued supply of D (en)
- Kombinovaná vakcína proti diftérii, tetanu a celobuněčné pertusi (DTPw) zůstává klíčovou složkou mnoha dětských očkovacích programů. Větší rozšíření vakcín na bázi DTPw podporuje vysoké pokrytí a ochranu proti dětským patogenům, jako jsou hepatitis A (HPV) a haemophylus influenzae typu B (Hib). Takové vakcíny jsou k dispozici od poloviny 90 let (Ttritanrix-HBV a Tritanrix-HBV/Hib) demonstrující výborný imunitní profil v různých schématech. Za účelem vyřešení rostoucího požadavku na DTPw založené vakcíny GSK biologicals vyvinulo Zilbrix za použití nového DTPw antigenního zdroje obsahujícího redukovaná kvanta polyribosylribitol phosphate [PRP]. Cíl: tento článek prezentuje klinická data pro obě DTPw vakcíny. Metody: GSK biologicals poskytlo všezahrnující datový balíček, který byl doprovázen vyhledáváním literatury systému Medline. Závěr: nové zdroje antigenů a redukovaného PRP zabezpečí, že kontinuální zásobování DTPw kombinovanými vakcínami pro klíčové globální masové očkovací kampaně. (cs)
|
| Title
| - Clinical experience with DTPw-HBV and DTPw-HBV/Hib combination vaccines
- Clinical experience with DTPw-HBV and DTPw-HBV/Hib combination vaccines (en)
- Klinická zkušenost s DTPw - HBV a DTPw-HBV/Hib kombinovanými vakcínami (cs)
|
| skos:prefLabel
| - Clinical experience with DTPw-HBV and DTPw-HBV/Hib combination vaccines
- Clinical experience with DTPw-HBV and DTPw-HBV/Hib combination vaccines (en)
- Klinická zkušenost s DTPw - HBV a DTPw-HBV/Hib kombinovanými vakcínami (cs)
|
| skos:notation
| - RIV/60162694:G44__/08:00001922!RIV09-MO0-G44_____
|
| http://linked.open...avai/riv/aktivita
| |
| http://linked.open...avai/riv/aktivity
| |
| http://linked.open...iv/cisloPeriodika
| |
| http://linked.open...vai/riv/dodaniDat
| |
| http://linked.open...aciTvurceVysledku
| |
| http://linked.open.../riv/druhVysledku
| |
| http://linked.open...iv/duvernostUdaju
| |
| http://linked.open...titaPredkladatele
| |
| http://linked.open...dnocenehoVysledku
| |
| http://linked.open...ai/riv/idVysledku
| - RIV/60162694:G44__/08:00001922
|
| http://linked.open...riv/jazykVysledku
| |
| http://linked.open.../riv/klicovaSlova
| - combination pediatric vaccines; diphtheria; DTPw-HBV/Hib; Haemophilus influenza type b; hepatitis B; tetanus; whole-cell pertussis (en)
|
| http://linked.open.../riv/klicoveSlovo
| |
| http://linked.open...odStatuVydavatele
| - GB - Spojené království Velké Británie a Severního Irska
|
| http://linked.open...ontrolniKodProRIV
| |
| http://linked.open...i/riv/nazevZdroje
| - Expert Opinion on Biological Therapy
|
| http://linked.open...in/vavai/riv/obor
| |
| http://linked.open...ichTvurcuVysledku
| |
| http://linked.open...cetTvurcuVysledku
| |
| http://linked.open...UplatneniVysledku
| |
| http://linked.open...v/svazekPeriodika
| |
| http://linked.open...iv/tvurceVysledku
| - Plíšek, Stanislav
- Prymula, Roman
|
| http://linked.open...n/vavai/riv/zamer
| |
| issn
| |
| number of pages
| |
| http://localhost/t...ganizacniJednotka
| |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)